Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function

I. Hoffmanová, D. Sánchez,

. 2018 ; 84 (4) : 796-799. [pub] 20180114

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu kazuistiky

Perzistentní odkaz   https://www.medvik.cz/link/bmc19028618

Topical carbonic anhydrase inhibitors (CAI), used for treatment of glaucoma, are generally regarded as safe and unconnected with systemic side effects. We report an unusual case of fatigue, metabolic acidosis, and normocytic anaemia associated with ocular administration of the CAI, dorzolamide, in a patient with impaired renal function. In chronic kidney disease, where CAI elimination may be decreased, and patients prone to develop metabolic acidosis, systemic absorption of ocular administered CAI could lead to rare, but potentially serious adverse reaction, that are a consequence of inhibition of extraocular carbonic anhydrase isoenzymes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028618
003      
CZ-PrNML
005      
20190822083302.0
007      
ta
008      
190813s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bcp.13499 $2 doi
035    __
$a (PubMed)29333622
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Hoffmanová, Iva $u Second Department of Internal Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function / $c I. Hoffmanová, D. Sánchez,
520    9_
$a Topical carbonic anhydrase inhibitors (CAI), used for treatment of glaucoma, are generally regarded as safe and unconnected with systemic side effects. We report an unusual case of fatigue, metabolic acidosis, and normocytic anaemia associated with ocular administration of the CAI, dorzolamide, in a patient with impaired renal function. In chronic kidney disease, where CAI elimination may be decreased, and patients prone to develop metabolic acidosis, systemic absorption of ocular administered CAI could lead to rare, but potentially serious adverse reaction, that are a consequence of inhibition of extraocular carbonic anhydrase isoenzymes.
650    _2
$a acidóza $x chemicky indukované $7 D000138
650    _2
$a aplikace oční $7 D060433
650    _2
$a anemie $x chemicky indukované $7 D000740
650    _2
$a inhibitory karboanhydras $x aplikace a dávkování $x škodlivé účinky $7 D002257
650    _2
$a únava $x chemicky indukované $7 D005221
650    _2
$a glaukom $x farmakoterapie $7 D005901
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a renální insuficience $x komplikace $7 D051437
650    _2
$a sulfonamidy $x aplikace a dávkování $x škodlivé účinky $7 D013449
650    _2
$a thiofeny $x aplikace a dávkování $x škodlivé účinky $7 D013876
655    _2
$a kazuistiky $7 D002363
700    1_
$a Sánchez, Daniel $u Laboratory of Cellular and Molecular Immunology, Institute of Microbiology of the Czech Academy of Sciences, v.v.i., Prague, Czech Republic.
773    0_
$w MED00000858 $t British journal of clinical pharmacology $x 1365-2125 $g Roč. 84, č. 4 (2018), s. 796-799
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29333622 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190822083540 $b ABA008
999    __
$a ok $b bmc $g 1433767 $s 1067078
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 84 $c 4 $d 796-799 $e 20180114 $i 1365-2125 $m British journal of clinical pharmacology $n Br J Clin Pharmacol $x MED00000858
LZP    __
$a Pubmed-20190813

Najít záznam

Citační ukazatele

Možnosti archivace